Strategy based on three key assets
Predilife is focusing its efforts on three main assets. MammoRisk in Europe is undergoing a clinical study with a publication timeline of approximately 18 months, deemed sufficient to attract potential industrial partners. In the United States, the FDA submission for DenSeerisk, which includes MammoRisk, is ongoing. Simultaneously, the multi-pathology predictive tests for corporate health check-ups have shown their commercial viability, with over 10,000 covered employees and agreements in place with major brokers and large companies in various sectors.
Reorganization and cash horizon
The internal activity of tests for employees, currently operating at a loss, will be discontinued as part of a restructuring planned for mid-April 2026. This measure will result in a significant reduction in the affected workforce and aims to limit the monthly cash consumption. After the receipt of the 2025 research tax credit, the company’s cash position will be around 300 kE with an estimated cash burn of 40 kE per month, providing a cash horizon until December 2026. The company will release its annual results for 2025 no later than May 15, 2026, and its annual financial report no later than May 30, 2026.
